Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy
Journal for ImmunoTherapy of Cancer · 2024-12 · 12 (12) · e010041
DOI: 10.1136/jitc-2024-010041 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 09.12.2024. Verfasst von Zhi Ji und 15 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Stomach Neoplasms, Neoadjuvant Therapy, Esophagogastric Junction. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: PhD Start-up Foundation of Tianjin Medical University Cancer Institute and Hospital, Tianjin Science and Technology Commission key project, Special Research Fund for Clinical Studies of Innovative Drugs after Market Launch.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Perioperative chemotherapy is the standard of care for patients with locally advanced gastric and gastroesophageal junction cancer. Recent evidence demonstrated the addition of programmed cell death protein 1 (PD-1) inhibitors enhanced therapeutic efficacy. However, the mechanisms of response and resistance remain largely undefined. A detailed multiomic investigation is essential to elucidate these mechanisms.
Methods
We performed whole-exome sequencing, whole-transcriptome sequencing, multiplex immunofluorescence and single-cell RNA sequencing on matched pretreatment and post-treatment samples from 30 patients enrolled in an investigator-initiated Phase 2 clinical trial ( NCT04908566 ). All patients received neoadjuvant PD-1 inhibitors in combination with chemotherapy. A major pathologic response (MPR) was defined as the presence of no more than 10% residual viable tumor cells following treatment.
Results
Before treatment, the positive ratio of CD3+T cells in both the tumor parenchyma and stroma was significantly higher in the non-MPR group compared with the MPR group (p=0.042 and p=0.013, respectively). Least absolute shrinkage and selection operator regression was employed for feature gene selection and 13 genes were ultimately used to construct a predictive model for identifying MPR after surgery. The model exhibited a perfect area under curve (AUC) of 1.000 (95% CI: 1.000 to 1.000, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer…
- Burning Rock Biotech Limited, Guangzhou, Guangdong, People's Republic of China.
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
ORCID-Profile: Jiaqi Xin
Förderung
- PhD Start-up Foundation of Tianjin Medical University Cancer Institute and Hospital
- Tianjin Science and Technology Commission key project
- Special Research Fund for Clinical Studies of Innovative Drugs after Market Launch
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Ji, Z., Wang, X., Xin, J., Ma, L., Zuo, D., Li, H., Su, L., Lv, X., Ge, S., Zhang, L., Liu, Y., Zhang, Y., Ding, T., Deng, T., Ba, Y., & Liu, R. (2024). Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy. Journal for ImmunoTherapy of Cancer, 12(12), e010041. https://doi.org/10.1136/jitc-2024-010041
Vancouver
Ji Z, Wang X, Xin J, Ma L, Zuo D, Li H, et al. Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy. Journal for ImmunoTherapy of Cancer. 2024;12(12):e010041. doi:10.1136/jitc-2024-010041
BibTeX
@article{Ji2024,
author = {Ji, Zhi and Wang, Xia and Xin, Jiaqi and Ma, Lijun and Zuo, Duo and Li, Hongli and Su, Lan and Lv, Xinze and Ge, Shaohua and Zhang, Le and Liu, Yong and Zhang, Yanhui and Ding, Tingting and Deng, Ting and Ba, Yi and Liu, Rui},
title = {Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {12},
pages = {e010041},
doi = {10.1136/jitc-2024-010041}
}
EUVIMED